Status:
UNKNOWN
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
Lead Sponsor:
Tongji Hospital
Conditions:
Hepatocellular Carcinoma
Programmed Cell Death 1
Eligibility:
All Genders
18+ years
Brief Summary
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the gl...
Detailed Description
This was a multi-center, retrospective study involving 2000 patients with HCC receiving ICIs (Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1)) and TKIs (Lenvatinib or ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of hepatocellular carcinoma
- Treated with ICIs (PD-1 or PDL-1) therapy plus TKIs (Lenvatinib or sorafenib)
- Treated with local therapy (TACE, HAIC, RF ablation, microwave ablation, radiotherapy, etc)
- Treated Treated with ICIs plus TKIs and local therapy
- Have complete medical record that can complete the OR or 1 year OS assessment and follow-up.
Exclusion
- Patients who do not have complete medical record and follow-up information after treatment；
- The researchers have evidence that it is not suitable for this study
Key Trial Info
Start Date :
November 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT05420922
Start Date
November 1 2021
End Date
December 31 2022
Last Update
June 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030